Which collaboration software company should be in your portfolio? Check out what sets Atlassian and Monday.com apart.Collaboration software is a hot ticket these days. From project management platforms to team-based communication tools, digital collaboration systems can help employees make the most of their talents and resources. Add in cloud-based availability from anywhere, a touch of process automation, and a dash of artificial intelligence (AI) assistance, and you have a productivity-boosting recipe.Sev ...

Final efficacy data expected in January 2025Anticipate resubmission of BLA in calendar Q1 2025 ISELIN, N.J., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom earlier this year for the first authorized use of an ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), today announced preliminary topline results of NORSE EIGHT, ...

New research shows the smartphone market recovering in 2024 following two years of sharp declines.However, Apple’s iPhone played just a small part in that recovery compared to rival Android phones, data released Tuesday (Nov. 26) by IDC shows.Global smartphone shipments for the year are projected to increase 6.2% to 1.24 billion units, IDC’s Worldwide Quarterly Mobile Phone Tracker shows. It’s a trend driven by “pent-up demand for device upgrades,” the research group said in a news release.And while this ye ...

I'm an insurance Case Manager with a deep interest in investing. My investment philosophy is all about buying high quality stocks and great businesses. My favorite businesses are those led by disciplined capital allocators, earn exceptional returns on capital, and can compound their invested capital over long periods of time.Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. ...

David Tepper's Appaloosa Management continues piling into Lyft as the company stages a comeback for the ages.David Tepper is a billionaire hedge fund manager known for founding the Miami-based investment firm Appaloosa Management. Back in September, he sat down for an interview with CNBC during which he expressed an outsized bullish stance on investing in China. Naturally, his comments led many investors to speculate which Chinese stocks the acclaimed investor may like.Well, thanks to 13F filings, investors ...

Advertisement Kohl's said comparable sales plummeted 9.3% in the third quarter.Apparel and footwear sales struggled despite strong performances for Sephora and other categories.Growth in revenue from beauty sales at Sephora was one of the few rays of hope.Kohl's continues to fight an uphill battle after sales tumbled following missed opportunities, a decline in footfall, and an overreliance on its partnership with Sephora.Comparable sales at the department store chain fell 9.3% in the three months to Novem ...

November 25th ended up being a very interesting day for shareholders of midstream/pipeline giant ONEOK (NYSE: OKE ). This is because the stock dropped after, the evening before, announcing that management had agreed to acquire the rest ofCrude Value Insights offers you an investing service and community focused on oil and natural gas. We focus on cash flow and the companies that generate it, leading to value and growth prospects with real potential.Subscribers get to use a 50+ stock model account, in-depth ...

文章核心观点 - 生物科技行业充满风险和机遇,Iovance Biotherapeutics作为新兴领导者,其TIL疗法具有革命性潜力,但公司仍需证明其商业模式的可行性 [1][2][9][13] Iovance TIL疗法突破 - 公司今年取得里程碑进展,2月获得FDA加速批准lifileucel,成为首个获批用于实体瘤和晚期黑色素瘤的细胞疗法 [4] - TIL疗法通过直接从患者肿瘤中提取T细胞,增强患者特定的自然抗癌反应,机制独特 [5] - 从肿瘤样本中制造个性化TIL单药疗法,作为一次性静脉输注,临床数据显示其持久反应和防止癌症恶化的能力,特别是在已对其他免疫疗法无效的晚期黑色素瘤患者中 [6] - 公司估计初始可寻址市场为每年30,000名患者,但通过扩展标签适应症,每年可能有超过70,000名患者受益,目前正在进行3期试验 [7] - 公司管线还包括lifileucel在非小细胞肺癌(NSCLC)中的应用,正在进行2期研究,考虑到全球患者群体更大,这可能是公司更大的收获 [8] 公司财务状况 - 公司第三季度总收入达到5900万美元,而去年同期不到50万美元,主要由于Amtagvi获批后患者入组加速 [10] - 预计2024年总收入在1.6亿至1.65亿美元之间,2025年将增至4.5亿至4.75亿美元,这是Amtagvi销售的第一年 [11] - 尽管收入增长强劲,但华尔街分析师预计公司今年每股亏损1.30美元,2025年亏损将缩小至每股0.82美元,由于持续的研发和全球扩张支出,盈利仍难以实现 [11] 投资前景 - 尽管Iovance显示出巨大潜力,但市场开始关注利润率和现金流等指标,这可能成为股价波动的财务阻力 [12] - 投资者还需要权衡临床数据令人失望的风险,这可能迫使公司重新评估其前景 [12] - Iovance Biotherapeutics可能仍处于重大增长机会的早期阶段,但成为多倍股并带来改变生活的回报仍存在重大不确定性 [13] - 如果对公司前景有信心,可以考虑在多元化投资组合中建立小仓位,但Iovance至少值得关注,以跟踪未来预期的发展 [14]

TEL AVIV, Israel, Nov. 27, 2024 (GLOBE NEWSWIRE) -- via IBN –  HUB Cyber Security Ltd. (NASDAQ: HUBC) (“HUB Security”; or the “Company”), a leading provider of cybersecurity solutions and advanced data fabric, has scheduled a conference call with management on Monday, December 2, 2024, at 9:00 a.m. ET, to review the first half 2024 results. Conference Call Details Date and Time: Monday, December 2, 2024, at 9:00 a.m. ET Call-in Information: Interested parties can access the conference call by dialing (844) ...

HOUSTON and LONDON, Nov. 27, 2024 (GLOBE NEWSWIRE) -- LyondellBasell (NYSE: LYB), a leader in the global chemical industry, today announced Michael McMurray, executive vice president and chief financial officer, will participate in a fireside chat at the 2024 Goldman Sachs Industrials and Materials Conference in New York on Wednesday, December 4, 2024, at 8 a.m. EST. Webcast and Presentation Slides AccessA live webcast can be accessed at the time of the event at https://investors.lyondellbasell.com/events-a ...